Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 5 (5), CD002021

Opioid Antagonists With Minimal Sedation for Opioid Withdrawal

Affiliations
Review

Opioid Antagonists With Minimal Sedation for Opioid Withdrawal

Linda Gowing et al. Cochrane Database Syst Rev.

Abstract

Background: Managed withdrawal is a necessary step prior to drug-free treatment or as the endpoint of long-term substitution treatment.

Objectives: To assess the effects of opioid antagonists plus minimal sedation for opioid withdrawal. Comparators were placebo as well as more established approaches to detoxification, such as tapered doses of methadone, adrenergic agonists, buprenorphine and symptomatic medications.

Search methods: We updated our searches of the following databases to December 2016: CENTRAL, MEDLINE, Embase, PsycINFO and Web of Science. We also searched two trials registers and checked the reference lists of included studies for further references to relevant studies.

Selection criteria: We included randomised and quasi-randomised controlled clinical trials along with prospective controlled cohort studies comparing opioid antagonists plus minimal sedation versus other approaches or different opioid antagonist regimens for withdrawal in opioid-dependent participants.

Data collection and analysis: We used standard methodological procedures expected by Cochrane.

Main results: Ten studies (6 randomised controlled trials and 4 prospective cohort studies, involving 955 participants) met the inclusion criteria for the review. We considered 7 of the 10 studies to be at high risk of bias in at least one of the domains we assessed.Nine studies compared an opioid antagonist-adrenergic agonist combination versus a treatment regimen based primarily on an alpha2-adrenergic agonist (clonidine or lofexidine). Other comparisons (placebo, tapered doses of methadone, buprenorphine) made by included studies were too diverse for any meaningful analysis. This review therefore focuses on the nine studies comparing an opioid antagonist (naltrexone or naloxone) plus clonidine or lofexidine versus treatment primarily based on clonidine or lofexidine.Five studies took place in an inpatient setting, two studies were in outpatients with day care, two used day care only for the first day of opioid antagonist administration, and one study described the setting as outpatient without indicating the level of care provided.The included studies were heterogeneous in terms of the type of opioid antagonist treatment regimen, the comparator, the outcome measures assessed, and the means of assessing outcomes. As a result, the validity of any estimates of overall effect is doubtful, therefore we did not calculate pooled results for any of the analyses.The quality of the evidence for treatment with an opioid antagonist-adrenergic agonist combination versus an alpha2-adrenergic agonist is very low. Two studies reported data on peak withdrawal severity, and four studies reported data on the average severity over the period of withdrawal. Peak withdrawal induced by opioid antagonists in combination with an adrenergic agonist appears to be more severe than withdrawal managed with clonidine or lofexidine alone, but the average severity over the withdrawal period is less. In some situations antagonist-induced withdrawal may be associated with significantly higher rates of treatment completion compared to withdrawal managed with adrenergic agonists. However, this result was not consistent across studies, and the extent of any benefit is highly uncertain.We could not extract any data on the occurrence of adverse events, but two studies reported delirium or confusion following the first dose of naltrexone. Delirium may be more likely with higher initial doses and with naltrexone rather than naloxone (which has a shorter half-life), but we could not confirm this from the available evidence.Insufficient data were available to make any conclusions on the best duration of treatment.

Authors' conclusions: Using opioid antagonists plus alpha2-adrenergic agonists is a feasible approach for managing opioid withdrawal. However, it is unclear whether this approach reduces the duration of withdrawal or facilitates transfer to naltrexone treatment to a greater extent than withdrawal managed primarily with an adrenergic agonist.A high level of monitoring and support is desirable for several hours following administration of opioid antagonists because of the possibility of vomiting, diarrhoea and delirium.Using opioid antagonists to induce and accelerate opioid withdrawal is not currently an active area of research or clinical practice, and the research community should give greater priority to investigating approaches, such as those based on buprenorphine, that facilitate the transition to sustained-release preparations of naltrexone.

Conflict of interest statement

Linda Gowing: none known.

Robert Ali: none known.

Jason White: none known.

Figures

Figure 1
Figure 1
Flow diagram of literature search
Figure 2
Figure 2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figure 3
Figure 3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Analysis 1.1
Analysis 1.1
Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 1 Peak withdrawal severity.
Analysis 1.2
Analysis 1.2
Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 2 Overall withdrawal severity.
Analysis 1.3
Analysis 1.3
Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 3 Completion rate.

Update of

  • Opioid Antagonists With Minimal Sedation for Opioid Withdrawal
    L Gowing et al. Cochrane Database Syst Rev (4), CD002021. PMID 19821290. - Review
    The use of opioid antagonists combined with alpha(2)-adrenergic agonists is a feasible approach to the management of opioid withdrawal. However, it is unclear whether thi …

Similar articles

  • Opioid Antagonists With Minimal Sedation for Opioid Withdrawal
    L Gowing et al. Cochrane Database Syst Rev (4), CD002021. PMID 19821290. - Review
    The use of opioid antagonists combined with alpha(2)-adrenergic agonists is a feasible approach to the management of opioid withdrawal. However, it is unclear whether thi …
  • Buprenorphine for Managing Opioid Withdrawal
    L Gowing et al. Cochrane Database Syst Rev 2 (2), CD002025. PMID 28220474. - Review
    Buprenorphine is more effective than clonidine or lofexidine for managing opioid withdrawal in terms of severity of withdrawal, duration of withdrawal treatment, and the …
  • Opioid Antagonists With Minimal Sedation for Opioid Withdrawal
    L Gowing et al. Cochrane Database Syst Rev (1), CD002021. PMID 16437438. - Review
    The use of opioid antagonists combined with alpha2 adrenergic agonists is a feasible approach to the management of opioid withdrawal. However, it is unclear whether this …
  • Alpha₂-adrenergic Agonists for the Management of Opioid Withdrawal
    L Gowing et al. Cochrane Database Syst Rev (5), CD002024. PMID 27140827. - Review
    Clonidine and lofexidine are more effective than placebo for the management of withdrawal from heroin or methadone. We detected no significant difference in efficacy betw …
  • Opioid Antagonists With Minimal Sedation for Opioid Withdrawal
    L Gowing et al. Cochrane Database Syst Rev (2), CD002021. PMID 12076431. - Review
    The use of opioid antagonists combined with alpha2 adrenergic agonists is feasible and probably increases the likelihood of transfer to naltrexone compared to withdrawal …
See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback